Candel (CADL) CEO Tak Paul Peter Sells Shares, Exercises Options

What Happened
Tak Paul Peter, CEO of Candel Therapeutics (CADL), exercised 125,000 option shares and immediately sold common stock in open-market transactions. He acquired 125,000 shares by exercising options at $1.55 per share (total cash paid $193,750). He then sold 220,866 shares at a weighted average price of $11.50 (proceeds $2,539,893) and 59,379 shares at a weighted average price of $10.46 (proceeds $620,891). Total proceeds from the sales were roughly $3.16 million. Overall this filing reports a net divestiture (sales) following an options exercise — a routine executive liquidity event rather than a disclosed purchase.

Key Details

• Transaction dates: exercises and first block of sales on 2026-09-10; additional sales on 2026-09-11. Form filed 2026-09-11 (timely).
• Exercise: 125,000 shares exercised (Form code M) at $1.55; cash outlay ~$193,750. The filing also lists the derivative instrument disposition related to that exercise.
• Sales: 220,866 shares sold at weighted avg $11.50 (range $11.20–$12.07 per footnote), and 59,379 shares sold at weighted avg $10.46 (range $9.86–$11.39 per footnote). Combined sales ≈ 280,245 shares for ≈ $3.16M.
• 10b5-1 plan: The September 10 sale(s) were effected under a 10b5-1 trading plan adopted 3/13/2026 and modified 6/11/2026 (per footnote).
• Vesting note: The option’s original vesting schedule is noted (initial vesting in 2020–2021 with monthly vesting thereafter).
• Shares owned after transaction: not reported in the materials you provided.

Context
This was an option exercise followed by open-market selling. The reported sales were executed under a 10b5-1 plan (pre-authorized trading plan), which is commonly used by insiders to systematically sell shares and reduce potential claims of trading on material nonpublic information. The filing is factual and routine — it documents an executive monetizing equity exposure, not a purchase that would signal insider bullishness.